Results 11 to 20 of about 1,503 (160)

Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate‐Lowering Response—In Search of a Minimum Effective Oxypurinol Concentration [PDF]

Clinical and Translational Science, 2020
The aims of this study were to determine factors that predict serum urate (SU) lowering response to allopurinol and the conversion of allopurinol to oxypurinol, and to determine a minimum therapeutic oxypurinol concentration.
Lisa K. Stamp, Peter T. Chapman, Murray Barclay, Anne Horne, Christopher Frampton, Tony R. Merriman, Daniel F. B. Wright, Jill Drake, Nicola Dalbeth   +8 more
doaj   +3 more sources

Response to Allopurinol and Febuxostat According to the Fractional Excretion of Urate in Men With Gout. [PDF]

Arthritis Care Res (Hoboken)
Objective Body mass index (BMI), glomerular filtration rate (GFR), and pretreatment urate levels have been reported to influence the urate‐lowering response to allopurinol. We investigated whether the fractional excretion of uric acid (FEUA) also modulates this response and relates to oxypurinol concentrations.
Richette P, Walter-Petrich A, Nguyen QD, Resche-Rigon M, Nguyen QHD, Do MD, Mai TP, Nguyen TD, Perez-Ruiz F, Letavernier E, Pascart T, Latourte A, Ea HK, Bardin T.   +13 more
europepmc   +2 more sources

Reduced Serum Urate Concentrations Despite Unchanged Allopurinol Dosing in Gout Patients Commenced on Dialysis: A Retrospective Chart Review. [PDF]

Nephrology (Carlton)
The study investigated allopurinol dosing practises and serum urate concentrations in gout patients with kidney failure following commencing dialysis. Results showed allopurinol dose was most commonly 100 mg, unadjusted upon commencing dialysis. However, serum urate concentrations significantly declined as patients commenced dialysis with more than 50%
Kamel N, Castelino R, Wright D, Sud K, Tarafdar S, Hughes S, Stocker S.   +6 more
europepmc   +2 more sources

A Pharmacometric Workflow for Resolving Model Instability in Model Use-Reuse Settings. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT The development of fit‐for‐purpose pharmacokinetic‐pharmacodynamic (PKPD) models based on clinical and pre‐clinical data is a critically important process in model informed drug development. This process is often hampered by modeling stability issues that are often multifactorial in nature and difficult to overcome, leading to protracted model
Duffull SB, Wright DFB, Zhu X, Liu X, Abulfathi A, Hishe H.   +5 more
europepmc   +2 more sources

An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites

Clinical and Translational Science, 2022
ABCG2 is a gene that codes for the human breast cancer resistance protein (BCRP). It is established that rs2231142 G>T, a single nucleotide polymorphism of the ABCG2 gene, is associated with gout and poor response to allopurinol, a uric acid‐lowering ...
Marc‐Olivier Pilon, Grégoire Leclair, Essaïd Oussaïd, Isabelle St‐Jean, Martin Jutras, Marie‐Josée Gaulin, Ian Mongrain, David Busseuil, Jean Lucien Rouleau, Jean‐Claude Tardif, Marie‐Pierre Dubé, Simon deDenus   +11 more
doaj   +1 more source

Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males

Clinical and Translational Science, 2023
Females present a higher risk of adverse drug reactions. Sex‐related differences in drug concentrations may contribute to these observations but they remain understudied given the underrepresentation of females in clinical trials.
Jessica Hindi, Marc‐Olivier Pilon, Maxime Meloche, Grégoire Leclair, Essaïd Oussaïd, Isabelle St‐Jean, Martin Jutras, Marie‐Josée Gaulin, Ian Mongrain, David Busseuil, Jean Lucien Rouleau, Jean‐Claude Tardif, Marie‐Pierre Dubé, Simon deDenus   +13 more
doaj   +1 more source

Xanthine oxidase and aldehyde oxidase contribute to allopurinol metabolism in rats

Journal of Pharmaceutical Health Care and Sciences, 2022
Background Allopurinol is used to treat hyperuricemia and gout. It is metabolized to oxypurinol by xanthine oxidase (XO), and aldehyde oxidase (AO). Allopurinol and oxypurinol are potent XO inhibitors that reduce the plasma uric acid levels.
Yoshitaka Tayama, Kazumi Sugihara, Seigo Sanoh, Katsushi Miyake, Shigeyuki Kitamura, Shigeru Ohta   +5 more
doaj   +1 more source

Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics

Clinical and Translational Science, 2021
The missense variant, breast cancer resistance protein (BCRP) p.Q141K, which encodes a reduced function BCRP, has been linked to poor response to allopurinol.
Bianca Vora, Deanna J. Brackman, Ling Zou, Maria Garcia‐Cremades, Marina Sirota, Radojka M. Savic, Kathleen M. Giacomini   +6 more
doaj   +1 more source

Evaluation of the Usefulness of Topological Indices for Predicting Selected Physicochemical Properties of Bioactive Substances with Anti-Androgenic and Hypouricemic Activity

Molecules, 2023
Due to the observed increase in the importance of computational methods in determining selected physicochemical parameters of biologically active compounds that are key to understanding their ADME/T profile, such as lipophilicity, there is a great need ...
Dawid Wardecki, Małgorzata Dołowy, Katarzyna Bober-Majnusz   +2 more
doaj   +1 more source

Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects [PDF]

British Journal of Clinical Pharmacology, 1996
1 Eight healthy subjects received 50, 100, 300, 600 and 900 mg allopurinol daily for 1 week each, in random order with 1 week separating each treatment period. The pre‐dose plasma concentration of oxypurinol, the extent of inhibition of xanthine oxidase, plasma urate concentration and urine urate excretion rate were assessed on the last 2 days of each
S, Graham, R O, Day, H, Wong, A J, McLachlan, L, Bergendal, J O, Miners, D J, Birkett   +6 more
openaire   +2 more sources